Analysts see higher drug sales for Cephalon NEW YORK - Sales of Cephalon Inc.'s muscle relaxant Amrix and cancer treatment Treanda will likely continue to drive revenue for the Frazer, Pa.-based drug developer, several analysts said Friday.Cephalon has somewhat shifted its focus to...
Analysts expect increasing sales of Cephalon's muscle relaxant and cancer treatment NEW YORK (AP) - Sales of Cephalon Inc.'s muscle relaxant Amrix and cancer treatment Treanda will likely continue to drive revenue for the Frazer, Pa.-based drug developer, several analysts said Friday.Cephalon has somewhat shifted its...
Analysts see higher drug sales for Cephalon Sales of Cephalon Inc.'s muscle relaxant Amrix and cancer treatment Treanda will likely continue to drive revenue for the Frazer, Pa.-based drug developer, several analysts said Friday.Cephalon has somewhat shifted its focus to Amrix and...
Analysts see higher drug sales for Cephalon Sales of Cephalon Inc.'s muscle relaxant Amrix and cancer treatment Treanda will likely continue to drive revenue for the Frazer, Pa.-based drug developer, several analysts said Friday.Cephalon has somewhat shifted its focus to Amrix and...
Analysts see higher drug sales for Cephalon Cephalon has somewhat shifted its focus to Amrix and Treanda following a negative recommendation from a Food and Drug Administration panel on the pain tablet Fentora. The drug is approved to treat severe pain flare-ups in cancer...
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players Introduction The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017.The growth in the market is spurred on by the uptake of Pfizer's Lyrica (pregabalin), forecast to reach...
Pipeline and Commercial Insight: Neuropathic Pain- UCB's Vimpat set to compete with major players Introduction The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017.The growth in the market is spurred on by the uptake of Pfizer's Lyrica (pregabalin), forecast to reach...
Cephalon Moves Ahead With Its RFID E-pedigree Plans International biopharmaceutical company Cephalon will enter a new phase in deploying RFID technology in its supply chain by affixing passive UHF RFID tags to cardboard shipping containers and serializing the EPC numbers on those tags that...
Pipeline and Commercial Insight: Neuropathic Pain Introduction The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017.The growth in the market is spurred on by the uptake of Pfizer's Lyrica (pregabalin), forecast to reach...
Cephalon sues Watson over Fentora patent _ Cephalon sues Watson over Fentora patent.
Cephalon Sues to Block Generic Fentora Check out our free and informative ezines and sign up now Sign Up Cephalon has filed a patent infringement suit to prevent the FDAs approval of Watsons generic version of its pain drug Fentora. Watson submitted its ANDA with a...
Cephalon Heads to Court to Stop Watson’s Generic Fentora Check out our free and informative ezines and sign up now This article is viewab Cephalon Heads to Court to Stop Watson’s Generic Fentora.
Cephalon files patent infringement lawsuit against Watson Cephalon, Inc.announced that it and its wholly-owned subsidiary CIMA LABS INC.
have filed a lawsuit in US District Court in Delaware against Watson Pharmaceuticals, Inc.
and its wholly-owned subsidiary, Watson Laboratories, Inc., for...
Cephalon files patent infringement lawsuit against Watson Pharmaceuticals The US patents do not expire until 2019.The lawsuit is based upon an abbreviated new drug application (ANDA) filed by Watson seeking FDA approval for a generic equivalent of fentanyl buccal tablets to be sold in the US.
Watson alleges...
Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for Fentora /PRNewswire-FirstCall/ -- Cephalon, Inc.announced today that a Joint Advisory Committee to the U.S.
Food and Drug Administration (FDA) voted not to recommend approval of an expanded label for FENTORA(R) (fentanyl buccal tablet) [C-II]...
UPDATE 2-Wider use of Cephalon drug too risky-US advisers (Reuters) - U.S.health officials should reject expanded use of Cephalon Inc's (CEPH.O: Quote, Profile, Research) Fentora pain drug beyond cancer patients because of the potential for abuse of the powerful narcotic, an advisory panel...
Cephalon: 'Not Surprised' by FDA Panel Vote A Food and Drug Administration advisory panel voted 17-to-3 Tuesday to recommend the regulatory agency not grant wider approval for Cephalon's CEPH The drug is currently approved to treat breakthrough pain, or severe pain in cancer patients...
FDA panel rejects expanded use for Fentora A Food and Drug Administration advisory panel voted 17-to-3 Tuesday against recommending an expanded marketing label for Fentora, a pain medicine marketed by Cephalon Inc.The FDA generally follows the recommendations of its advisory...
On the Watch: Cisco and Disney report quarterly results NEW YORK (AP) - Shares of Cisco Systems Inc.may see heavy trading Wednesday after the networking equipment maker posted a larger-than-expected profit in its fiscal third quarter.
Cisco's profit fell 5 percent for the quarter, but its...
Cephalon: FDA panel votes against approval of expanded label for Fentora SAN FRANCISCO (Thomson Financial) - Cephalon Inc.late Tuesday said a joint advisory committee to the Food and Drug Administration voted not to recommend approval of an expanded label for Fentora for the management of breakthrough...
U.S. FDA concerned over wider Cephalon pain drug use WASHINGTON (Reuters) - Allowing Cephalon Inc to market its Fentora pain drug more widely for patients without cancer could have 'devastating effects,' a U.S.Food and Drug Administration official said in documents released on Friday....
Watson files ANDA for generic Fentora Watson Pharmaceuticals, Inc, a leading specialty pharmaceutical company, said its subsidiary Watson Laboratories, Inc.has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to...
FDA discouraging expanded use of Cephalon painkiller A Food and Drug Administration official said in documents released today that allowing Cephalon Inc.to sell its Fentora pain drug more widely for patients without cancer could lead to potentially fatal abuse.Fentora, a potent...
U.S. FDA concerned over wider Cephalon pain drug use WASHINGTON Approving Cephalon Inc's Fentora pain drug for patients without cancer could have devastating effects, a Food and Drug Administration official said in documents released Friday.The company is seeking wider U.S.
approval...
UPDATE 1-US FDA concerned over wider Cephalon pain drug use (Reuters) - Approving Cephalon Inc's (CEPH.O: Quote, Profile, Research) Fentora pain drug for patients without cancer could have 'devastating effects,' a U.S.Food and Drug Administration official said in documents released on Friday...
